1. Home
  2. GPRE vs GERN Comparison

GPRE vs GERN Comparison

Compare GPRE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Green Plains Inc.

GPRE

Green Plains Inc.

HOLD

Current Price

$17.06

Market Cap

812.2M

Sector

Industrials

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.43

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRE
GERN
Founded
2004
1990
Country
United States
United States
Employees
N/A
258
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
812.2M
808.3M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
GPRE
GERN
Price
$17.06
$1.43
Analyst Decision
Buy
Hold
Analyst Count
7
3
Target Price
$12.57
$2.17
AVG Volume (30 Days)
1.3M
10.3M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
$2,091,680,000.00
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$11.85
$43.75
P/E Ratio
$40.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.08
$1.04
52 Week High
$19.65
$2.01

Technical Indicators

Market Signals
Indicator
GPRE
GERN
Relative Strength Index (RSI) 53.76 53.59
Support Level $14.01 $1.39
Resistance Level $17.94 $1.46
Average True Range (ATR) 0.96 0.08
MACD 0.04 -0.01
Stochastic Oscillator 40.46 27.78

Price Performance

Historical Comparison
GPRE
GERN

About GPRE Green Plains Inc.

Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: